Acadian Asset Management LLC Buys Shares of 1,543 DaVita Inc. (NYSE:DVA)

Acadian Asset Management LLC purchased a new position in shares of DaVita Inc. (NYSE:DVA) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 1,543 shares of the company’s stock, valued at approximately $212,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Blue Trust Inc. grew its holdings in DaVita by 58.6% during the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after acquiring an additional 78 shares during the period. Wedmont Private Capital boosted its holdings in DaVita by 6.0% during the second quarter. Wedmont Private Capital now owns 1,701 shares of the company’s stock worth $241,000 after purchasing an additional 96 shares during the last quarter. First Trust Direct Indexing L.P. boosted its holdings in DaVita by 3.9% during the first quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company’s stock worth $358,000 after purchasing an additional 98 shares during the last quarter. Quent Capital LLC increased its stake in DaVita by 21.0% in the 1st quarter. Quent Capital LLC now owns 581 shares of the company’s stock valued at $80,000 after buying an additional 101 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of DaVita by 18.8% during the 1st quarter. GAMMA Investing LLC now owns 657 shares of the company’s stock worth $91,000 after buying an additional 104 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Performance

NYSE DVA opened at $164.00 on Friday. The firm has a market cap of $14.38 billion, a price-to-earnings ratio of 18.64, a PEG ratio of 0.95 and a beta of 0.87. The company has a 50-day simple moving average of $147.19 and a two-hundred day simple moving average of $140.85. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. DaVita Inc. has a 12-month low of $71.51 and a 12-month high of $166.04.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.47 by $0.12. The company had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a return on equity of 77.00% and a net margin of 6.86%. DaVita’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.08 EPS. On average, equities analysts forecast that DaVita Inc. will post 9.99 EPS for the current year.

Insider Activity

In other DaVita news, CFO Joel Ackerman sold 64,029 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the sale, the chief financial officer now owns 111,481 shares of the company’s stock, valued at approximately $17,286,243.86. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares of the company’s stock, valued at $138,284,666.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Joel Ackerman sold 64,029 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the sale, the chief financial officer now directly owns 111,481 shares of the company’s stock, valued at approximately $17,286,243.86. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 173,482 shares of company stock valued at $27,387,069. 2.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. UBS Group lifted their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. TD Cowen upped their price target on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Truist Financial increased their price objective on DaVita from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Tuesday, August 20th. Finally, Bank of America raised their target price on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat, DaVita has a consensus rating of “Hold” and a consensus price target of $157.00.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.